<DOC>
	<DOCNO>NCT02564354</DOCNO>
	<brief_summary>Exploratory proof concept study determine whether intranasal administration QR-010 subject cystic fibrosis , homozygous compound heterozygous ΔF508 mutation , increase function Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) .</brief_summary>
	<brief_title>Exploratory Study Evaluate QR-010 Subjects With Cystic Fibrosis ΔF508 CFTR Mutation</brief_title>
	<detailed_description>This open-label , multi-center , exploratory study estimate effect intranasal administration QR-010 nasal mucosa restoration CFTR function , measure nasal potential difference ( NPD ) , nasal epithelium adult subject CF homozygous compound heterozygous ΔF508 CFTR mutation .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF define iontophoretic pilocarpine sweat chloride test ( sweat chloride ) &gt; 60 mmol/L Nasal potential difference ( NPD ) measurement Screening consistent CF Confirmation CFTR gene mutation homozygous compound heterozygous ΔF508 mutation Body mass index ( BMI ) ≥ 18 kg/m2 Nonsmoking minimum 2 year Stable lung function FEV1 ≥40 % predict normal age , gender , height Screening Breastfeeding pregnant Acute allergy infection affect nasal condition resolve within 14 day prior Screening Use lumacaftor ivacaftor Use investigational drug device Hemoptysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>ΔF508</keyword>
	<keyword>CFTR</keyword>
	<keyword>QR-010</keyword>
	<keyword>antisense oligonucleotide</keyword>
	<keyword>RNA therapy</keyword>
	<keyword>F508del</keyword>
	<keyword>NPD</keyword>
	<keyword>nasal potential difference</keyword>
</DOC>